Company Overview and News

KLCI up 0.79% in technical rebound, Maybank and TNB lift

2018-10-12 theedgemarkets
KUALA LUMPUR (Oct 12): The FBM KLCI rose 0.79% in a technical rebound at the midday break today, snapping its seven-day losing streak, lifted by index heavyweights including Malayan Banking Bhd (Maybank) and Tenaga Nasional Bhd (TNB).
HLFBF MLYBY MLYNF 7036 1082 7006 5135 6033 5199 CIMDF 1155 KLKBY 1023 2445 PNADF 5347 TNABY 6888 0006 5819 AXXTF TNABF HIPEF PNAGF

Worst may be over for Ta Ann’s timber business

2018-09-05 theedgemarkets
TA Ann Holdings Bhd’s timber business, which has been loss-making for the past three consecutive quarters, may have turned a corner.
5135 5012

Econpile, Apex Healthcare, Carlsberg, Daibochi, Dialog, Hock Seng Lee, KPJ, Sarawak Plantation, SunCon and Warisan TC

2018-08-16 theedgemarkets
KUALA LUMPUR (Aug 16): Based on corporate announcements and news flow today, stocks in focus tomorrow may include the following: Econpile Holdings Bhd, Apex Healthcare Bhd, Carlsberg Brewery Malaysia Bhd, Daibochi Bhd, Dialog Group Bhd, Hock Seng Lee Bhd, KPJ Healthcare Bhd, Sarawak Plantation Bhd, Sunway Construction Group Bhd and Warisan TC Holdings Bhd. Econpile Holdings Bhd secured a contract worth RM30.
APEXF KPJHF 5016 7090 6238 5878 5253 5263 2836 5135 7277

Sarawak Plantation 2Q net profit nearly halved on lower ASP, sales

2018-08-16 theedgemarkets
KUALA LUMPUR (Aug 16): Sarawak Plantation Bhd’s net profit nearly halved to RM2.39 million for the quarter ended June 30, 2018 (2QFY18) from RM4.22 million a year ago, in line with its lower realised average selling price (ASP) and lower sales volume of crude palm oil (CPO) and palm kernel (PK).

Stormy quarter puts pressure on Ta Ann’s cash flow

2018-06-13 theedgemarkets
BAD luck and ongoing timber woes are sapping the cash reserves of Ta Ann Holdings Bhd, which paid nearly RM171 million for 30.4% of Sarawak Plantation Bhd (SPLB) earlier this year.
5135 5012

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...